Kymera Therapeutics Inc Q2 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : First, also on the QT prolongation. You mentioned this is probably related to -- specifically to the molecule. I was wondering if you have identified any liable structures within the compound that is for those? And I guess the question is really to ask whether other compounds in your pipeline have this liable structure. Follow up on the second ask whether other compounds your pipeline have this liable structure? I had a follow-up on the potential efficacy of this IRAK4 plan. Help us understand kind of frame the efficacy expectation for IRAK4 AD and HS. I'm not looking for guidance, but just kind of broadly speaking, in terms of different modalities. I think Sanofi talked about they're not looking as a biologic, but they see a great potential for part of therapy.

Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst : Moving just to STAT3, I guess what are you expecting to see from a PD perspective and proof of mechanism perspective, such as the percent degradation at the update later this year just based on the doses you're studying, I understand that it's still in dose escalation. And then just in terms of STAT3, I guess what have we learned from kind of some other STAT3 clinical programs, whether it's inhibitors or anti-sense programs targeting STAT3, just from a clinical perspective in terms of any efficacy seen in the oncology setting and lessons learned there? And I guess, kind of what we've learned about why it's so important to degrade versus inhibit STAT3?